<DOC>
	<DOCNO>NCT02649569</DOCNO>
	<brief_summary>This pilot research trial study continuous activity monitoring fractionate radiotherapy patient head neck , lung , gastrointestinal cancer . This study explore use fitness tracker study activity level patient , , radiation therapy use weekly assessment measure patient ' quality life radiation therapy . This may allow doctor see relationship activity level , quality life , treatment interruption , hospitalization , clinical outcome .</brief_summary>
	<brief_title>Continuous Activity Monitoring During Fractionated Radiotherapy Patients With Head Neck , Lung , Gastrointestinal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To demonstrate feasibility continuous , accelerometer-based evaluation patient activity level , , treatment fractionate external beam radiotherapy . SECONDARY OBJECTIVES : I . To demonstrate feasibility perform weekly quality life assessment fractionate external beam radiotherapy . II . To explore accelerometer-based metric change throughout patient ' treatment course change associate quality life assessment , treatment interruption , hospitalization , clinical outcome . OUTLINE : Patients wear activity monitor throughout 4 week completion radiation therapy . Patients willing may continue wear monitor routine follow appointment . Patients also complete questionnaire evaluation , take place prior radiotherapy initiation , weekly radiotherapy , 2 4 week completion radiotherapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Able ambulate independently ( without assistance cane walker ) Diagnosis invasive malignancy head neck region , lung , gastrointestinal tract Planned treatment fractionate ( &gt; = 15 treatment ) external beam radiotherapy concurrent chemotherapy curative intent Women childbearing potential must : Have negative serum urine pregnancy test within 72 hour prior start study therapy Agree utilize adequate method contraception throughout treatment least 4 week study therapy complete Be advise importance avoid pregnancy trial participation potential risk unintentional pregnancy All patient must sign study specific informed consent prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>